Dennis Huang

899 total citations
19 papers, 553 citations indexed

About

Dennis Huang is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Dennis Huang has authored 19 papers receiving a total of 553 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 9 papers in Molecular Biology and 7 papers in Oncology. Recurrent topics in Dennis Huang's work include Prostate Cancer Treatment and Research (5 papers), Cancer, Lipids, and Metabolism (3 papers) and Growth Hormone and Insulin-like Growth Factors (3 papers). Dennis Huang is often cited by papers focused on Prostate Cancer Treatment and Research (5 papers), Cancer, Lipids, and Metabolism (3 papers) and Growth Hormone and Insulin-like Growth Factors (3 papers). Dennis Huang collaborates with scholars based in United States, Germany and China. Dennis Huang's co-authors include Andrea Sboner, Deli Liu, Christopher E. Barbieri, Mark A. Rubin, Mirjam Blattner, Brian D. Robinson, Lesa D. Deonarine, Srilakshmi Nataraj, Michael A. Augello and Yu Chen and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Cell.

In The Last Decade

Dennis Huang

18 papers receiving 549 citations

Peers

Countries citing papers authored by Dennis Huang

Since Specialization

Citations

This map shows the geographic impact of Dennis Huang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dennis Huang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dennis Huang more than expected).

Fields of papers citing papers by Dennis Huang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dennis Huang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dennis Huang. The network helps show where Dennis Huang may publish in the future.

Co-authorship network of co-authors of Dennis Huang

This figure shows the co-authorship network connecting the top 25 collaborators of Dennis Huang. A scholar is included among the top collaborators of Dennis Huang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dennis Huang. Dennis Huang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	EXTH-20. A MOUSE MODEL REVEALS VULNERABILITY OF IDH1-MUTATED GLIOMA TO FERROPTOSIS 2023 ·Neuro-Oncology ·Angeliki Mela, Athanassios Dovas, Aayushi Mahajan, Nelson Humala, Trang Nguyen, (unknown), Pavan S. Upadhyayula, (unknown), Michael Argenziano, Dennis Huang, Jia Guo, Patrizia Casaccia, Markus D. Siegelin, Brent R. Stockwell, Jeffrey N. Bruce, Peter Canoll	0
2	Biomarker Subset Analysis of a Phase IIIb, Open-Label Study of Afatinib in EGFR Tyrosine Kinase Inhibitor-Naive Patients with EGFR m+ Non-Small-Cell Lung Cancer 2022 ·Future Oncology ·Jun Zhao, Hua Bai, Xin Wang, Yuyan Wang, Jianchun Duan, Hanxiao Chen, (unknown), (unknown), A. Cseh, Dennis Huang, Yi‐Long Wu, Jie Wang	1
3	Prenatal Exposure to a Climate-Related Disaster Results in Changes of the Placental Transcriptome and Infant Temperament 2022 ·Frontiers in Genetics ·Jessica L. Buthmann, Dennis Huang, Patrizia Casaccia, Sarah O’Neill, Yoko Nomura, Jia Liu	3
4	ACTL6a coordinates axonal caliber recognition and myelination in the peripheral nerve 2022 ·iScience ·(unknown), (unknown), Dennis Huang, Michael R. Weaver, Luciana Romina Frick, (unknown), John J. Moran, Julia Patzig, Carmen V. Melendez‐Vasquez, Robert H. Crabtree, M. Laura Feltri, John Svaren, Patrizia Casaccia	6
5	G3BP1 inhibits Cul3SPOP to amplify AR signaling and promote prostate cancer 2021 ·Nature Communications ·(unknown), Chenyi Yang, Limei Xu, Deli Liu, Yu Wang, Dennis Huang, Lesa D. Deonarine, Joanna Cyrta, Elai Davicioni, Andrea Sboner, Brian D. Robinson, Arul M. Chinnaiyan, Mark A. Rubin, Christopher E. Barbieri, Pengbo Zhou	27
6	Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivity 2021 ·Cell Reports ·Ivana Grbeša, Michael A. Augello, Deli Liu, Dylan McNally, Christopher Gaffney, Dennis Huang, Kevin Lin, (unknown), Ramy Goueli, Brian D. Robinson, Francesca Khani, Lesa D. Deonarine, Mirjam Blattner, Olivier Elemento, Elai Davicioni, Andrea Sboner, Christopher E. Barbieri	23
7	TET1-mediated DNA hydroxymethylation regulates adult remyelination in mice 2021 ·Nature Communications ·Sarah Moyon, Rebecca Frawley, Damien Maréchal, Dennis Huang, (unknown), Linde Kegel, (unknown), Boguslawa Sadowski, Yong‐hui Jiang, David A. Lyons, Wiebke Möbius, Patrizia Casaccia	48
8	Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors 2021 ·JTO Clinical and Research Reports ·Keunchil Park, Daniel S.W. Tan, Wu‐Chou Su, Byoung Chul Cho, Sang‐We Kim, Ki Hyeong Lee, Chin‐Chou Wang, Takashi Seto, Dennis Huang, (unknown), (unknown), Thomas Bogenrieder, Chia‐Chi Lin	5
9	A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer 2021 ·Breast Cancer Research ·Peter Schmid, Marie‐Paule Sablin, Jonas Bergh, Seock‐Ah Im, Yen‐Shen Lu, Noelia Martínez-Jáñez, Patrick Neven, Keun Seok Lee, Serafín Morales, José Alejandro Pérez Fidalgo, Douglas Adamson, Anthony Gonçalvès, Aleix Prat, Guy Jérusalem, (unknown), (unknown), Thomas Bogenrieder, Dennis Huang, John Crown, Javier Cortés	17
10	Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations, previously treated with chemotherapy: A phase II trial 2020 ·Lung Cancer ·Yun Fan, Jianhua Chen, Chengzhi Zhou, Huijuan Wang, Yongqian Shu, (unknown), (unknown), Dennis Huang, Caicun Zhou	29
11	Dynamic Lamin B1-Gene Association During Oligodendrocyte Progenitor Differentiation 2020 ·Neurochemical Research ·(unknown), Marylens Hernandez, Dennis Huang, (unknown), Will Liao, Patrizia Casaccia	8
12	Abstract P3-11-05: A phase Ib multi-cohort study of xentuzumab and abemaciclib in patients (pts) with solid tumors and breast cancer (BC) - Initial report of four dose-finding cohorts 2020 ·Cancer Research ·Douglas Yee, Mafalda Oliveira, Hiroji Iwata, Anthony Gonçalvès, Javier García-Corbacho, (unknown), Aleix Prat, Molly Catherine Hardebeck, Marta Puig, Dennis Huang, (unknown), Patricia LoRusso	1
13	CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis 2019 ·Cancer Cell ·Michael A. Augello, Deli Liu, Lesa D. Deonarine, Brian D. Robinson, Dennis Huang, Suzan Stelloo, Mirjam Blattner, Ashley S. Doane, Elissa W.P. Wong, Yu Chen, Mark A. Rubin, Himisha Beltran, Olivier Elemento, Andries M. Bergman, Wilbert Zwart, Andrea Sboner, Noah Dephoure, Christopher E. Barbieri	83
14	A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma 2018 ·Liver Cancer ·Chia-Jui Yen, Tae‐You Kim, Yin‐Hsun Feng, Yee Chao, Deng‐Yn Lin, Baek‐Yeol Ryoo, Dennis Huang, David Schnell, (unknown), Arsène‐Bienvenu Loembé, Ann‐Lii Cheng	21
15	SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling 2017 ·Cancer Cell ·Mirjam Blattner, Deli Liu, Brian D. Robinson, Dennis Huang, Anton Poliakov, Dong Gao, Srilakshmi Nataraj, Lesa D. Deonarine, Michael A. Augello, Verena Sailer, Lalit Ponnala, Michael Ittmann, Arul M. Chinnaiyan, Andrea Sboner, Yu Chen, Mark A. Rubin, Christopher E. Barbieri	140
16	P3.02b-005 Phase Ib Trial of Afatinib and BI 836845 in Advanced NSCLC: Dose Escalation and Safety Results 2017 ·Journal of Thoracic Oncology ·Keunchil Park, Byoung Chul Cho, Ki Hyeong Lee, Wu‐Chou Su, Sang‐We Kim, Chia‐Chi Lin, Dennis Huang, (unknown), Yuan Geng, Daniel S.W. Tan	1
17	Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics 2017 ·Journal of Translational Medicine ·Hui Wang, Christopher E. Barbieri, Jintang He, Yuqian Gao, Tujin Shi, Chaochao Wu, Athena Schepmoes, Thomas Fillmore, Sung‐Suk Chae, Dennis Huang, Juan Miguel Mosquera, Weijun Qian, Richard Smith, Sudhir Srivastava, Jacob Kagan, David Camp, Karin Rodland, Mark A. Rubin, Tao Liu	5
18	SPOP mutation leads to genomic instability in prostate cancer 2015 ·eLife ·Gunther Boysen, Christopher E. Barbieri, Davide Prandi, Mirjam Blattner, Sung‐Suk Chae, (unknown), Srilakshmi Nataraj, Dennis Huang, Clarisse Marotz, Limei Xu, Julie Huang, Paola Lecca, Sagar Chhangawala, Deli Liu, Pengbo Zhou, Andrea Sboner, Johann S. de Bono, Francesca Demichelis, Yariv Houvras, Mark A. Rubin	132
19	A phase I dose escalation study of weekly BI 836845, a fully human, affinity-optimized, insulin-like growth factor (IGF) ligand neutralizing antibody, in patients with advanced solid cancers. 2014 ·Journal of Clinical Oncology ·Chia‐Chi Lin, Kwang‐Yu Chang, Dennis Huang, (unknown), Ludy van Beijsterveldt, Li‐Tzong Chen, Ann‐Lii Cheng	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact